Country: Australia
Language: English
Source: Department of Health (Therapeutic Goods Administration)
apixaban, Quantity: 5 mg
Cipla Australia Pty Ltd
Tablet, film coated
Excipient Ingredients: lactose monohydrate; microcrystalline cellulose; croscarmellose sodium; sodium lauryl sulfate; magnesium stearate; titanium dioxide; hypromellose; iron oxide red; macrogol 400
Oral
10 tablets, 14 tablets, 28 tablets, 60 tablets
(S4) Prescription Only Medicine
APIXABAN CIPLA is indicated for the prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective total hip or total knee replacement surgery.,APIXABAN CIPLA is indicated for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation and at least one additional risk factor for stroke.,APIXABAN CIPLA is indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) in adult patients.,APIXABAN CIPLA is indicated for the prevention of recurrent DVT and PE in adult patients.
Visual Identification: Pink, oval, bocinvex, film-coated tablet plain on both sides; Container Type: Blister Pack; Container Material: PVC/PVDC/Al; Container Life Time: 10 Months; Container Temperature: Store below 30 degrees Celsius
Registered